Choice of baseline in a multiple-dose thorough QT study (TQTs) – effect on analysis of moxifloxacin-induced QTc prolongation

B Tyl 1
S Azzam 2
E Reinbolt 2
N Blanco 1
J Olbertz 3
W Wheeler 1

1 MDS Pharma Services, Centralized Cardiac Services, Baillet-en-France, France; 2 MDS Pharma Services, Early Clinical Research, Lincoln (Nebraska), USA; 3 MDS Pharma Services, Early Clinical Research, Phoenix (Arizona), USA

Background: The primary endpoint of a thorough QT study (TQTs) is the change from baseline in QT corrected (QTc) measured on electrocardiograms (ECG) tracings. It has been suggested that during a crossover study, the time-matched or predose baseline could be recorded. The choice of method for baseline ECG collection may influence the results and the cost of the TQTS.

Objective: The objective of our study was to compare the collection of a time-matched baseline before each period (TM EACH), an average of all the time-matched baseline (TM MEAN), a time-matched baseline before period 1 (TM P1), and a predose baseline (PD EACH) on QT interval prolongation induced by moxifloxacin, in a 30 subjects, 5 arm cross-over TQTS.

Results: Moxifloxacin induced a similar significant increase in QT corrected using Fridericia’s formula (QTc) (lower limit of the confidence interval excluded 5 ms) at all time-points between 0.5 hours and 12 hours with all baseline methods. TM EACH was associated with a lower within subject variability (SD 5.59 ms) than TM MEAN and TM P1 (5.90 and 6.90 ms, respectively). PD EACH was associated with the highest variability (7.41 ms).

Conclusion: The collection of ECG tracings during a full baseline day before each period was associated with the lowest variability. However, the two more cost effective designs (TM P1 and PD EACH) were sufficient, in this small TQTS, to significantly detect moxifloxacin.

Keywords: thorough QT study, QT correction, baseline, design, superimposed representative complex, moxifloxacin

Introduction

The ability of many drugs to delay cardiac repolarization leading to cardiac arrhythmias such as “Torsades de Pointes” and subsequent sudden death, has been a concern for over two decades. 2-5 Consequently, the International Conference on Harmonization (ICH) Guidance E14 6 was issued in 2005 to provide recommendations on design, conduct, analysis, and interpretation of clinical studies for the assessment of proarrhythmic potential of non-antiarrhythmic drugs. It recommends conduct of a “thorough QT/QTc” study (TQTS) to measure the effect of a drug on the QT interval early in development to determine the need for intensive QT monitoring during later development. The TQTS compares the QT and heart-rate corrected QT (QTc) intervals of the study with the drug administered at therapeutic and supra-therapeutic doses compared to that of placebo after correction for baseline QT/QTc intervals. Additionally, to assess the sensitivity of the study, a drug known to increase the QT interval near the threshold of regulatory concern (+5 ms) should be used as a positive control. Because QT is highly variable, the primary end-point is defined as the upper limit of
the one-sided 95% confidence interval (CI) of the maximum QT/QTc change.

Since the QT interval is affected by factors that might vary depending on the time of day, eg circadian rhythm,1–9 food ingestion,10 physical activity, and postural changes,11 the guidance suggests the collection of electrocardiograms (ECGs) at multiple time points (at baseline and after dosing), and states that the effect of the drug on the QT/QTc interval “is most commonly analyzed using the largest time-matched mean difference between the drug and placebo (baseline-adjusted) over the collection period”. Several different methods for baseline collection have been proposed12 including time-matched methods (requiring a 24-hour baseline before each test period) and predose baseline (average of several predose time points). A predose baseline has been shown to be effective in single dose TQTs,13,14 although the impact of baseline methods in multiple dose TQTs could be different due to day-to-day QT variability.

Methods
Subjects and study design
This was a multiple-dose (once daily for 4 days), randomized, triple dummy, double-blind, 5-way crossover study (placebo control, active control of 400 mg moxifloxacin, therapeutic and supra-therapeutic doses of study drug, and therapeutic study drug dose co-administered with a CYP P450 inhibitor). Blinding of moxifloxacin was ensured by over encapsulation. Thirty subjects were enrolled and 28 subjects completed the study which was conducted at MDS Pharma Services, Phoenix, Arizona in accordance with the Declaration of Helsinki and Good Clinical Practice.

Participants completed 5 confinement periods with a minimum 7-day washout between periods. For each period, subjects were admitted to the clinic at least 12 hours prior to the start of baseline ECG collections on Day 1 and remained confined until completion of events on Day 7. Subjects were awakened at least 1 hour prior to the start of ECG collections and were not allowed to sleep during the day because the QT-RR relationship is different during sleep.15 The QT is also influenced by meals16 therefore, subjects fasted for 8 hours prior to and 4 hours following each dosing and during the same time interval on Day 1. No ECGs were recorded less than 1 hour after a meal.

Timing, recording, and interpretation of ECGs
Three 10-second digital ECG recordings were obtained within a 2-minute window using a GE Healthcare Mac 12000 device (Milwaukee, Wisconsin, USA) at: Hour 0 (predose), 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, and 24 on Day 1 and Day 4, Hours 36 and 48 (Day 5), and Hour 72 (Day 6).

Tracings were digitally transmitted to a central ECG laboratory (MDS PS Baillet-en-France, France) for interpretation. All ECG interval durations for each subject were measured semi-automatically on 12 superimposed representative complexes16 in a random order by the same cardiologist blinded to collection time and treatment, using Trace® (Cardionics, Brussels, Belgium) software. The software prepositioned the calipers that were then adjusted as needed by the cardiologist. Once the intervals were measured, the cardiologist performed a rhythm, morphology, and repolarization assessment. Discrete U waves were excluded from the QT/QTc interval measurement.

The mean RR interval of the 10 second tracing was used to obtain heart rate corrected QT intervals (Fridericia’s correction; QTcF = QT/[RR]1/3). The relation between QT and RR intervals has been shown to be highly individual among healthy subjects18 and the use of subject specific QT/RR corrections (QTcI) has been proposed for pharmacological studies.19 If the active drug is associated with a change in heart rate, the QTcI is superior to QTcF in correcting the QT interval for heart rate; if there is minimal change in heart rate, QTcF is sufficient. The calculation of a robust QTcI requires the recording of at least 50 to 100 off-treatment ECG tracings20 that can only be recorded during full baseline days making the predose method unsuitable. In our study, as no significant change in heart rate was noted (the maximum increase in HR during the first 12 hours was noted at one time point in the moxifloxacin group and did not exceed 4 bpm), the QTcF sufficiently corrected the QT interval for heart rate.

Statistical analysis of QTc intervals
Baselines
The 4 methods for measuring baseline QT/QTc intervals were: a) 24-hour, time-matched baseline from each period (TM\textsubscript{EACH}). b) 24-hour, time-matched baseline from the mean of all periods (TM\textsubscript{MEAN}). c) 24-hour, time-matched baseline from the first period only (TM\textsubscript{P1}). d) Predose (Hour 0) value of each period as the baseline (PD\textsubscript{EACH}).

For each time point, the average of the triplicate QTcF intervals was calculated and recorded as the QTcF for that time point. The change from baseline in QTcF (ΔQTcF) on Day 4 was calculated for each subject with the three 24 hour, time-matched baselines (TM\textsubscript{EACH}, TM\textsubscript{MEAN}, and TM\textsubscript{P1}) using the QTcF at each time point on Day 4 and the QTcF at the corresponding time point on Day 1.
The predose baseline was the QTcF at Hour 0 on Day 1 of each period. For each subject, the ΔQTcF on Day 4 was calculated as the difference between the QTcF on Day 4 and the baseline value from the corresponding period. All four methods are described in Figure 1.

Statistical model

The ΔQTcF values were subjected to an analysis of covariance (ANCOVA) for repeated measures, with each subject’s baseline value (BL) being the covariate. The model included factors for enrolment group, period, sequence, and treatment. Depending on the baseline scenario, BL was either each subject’s time-matched baseline value or each subject’s predose baseline value. The repeated variable was the time point. The covariance structure was specified as compound symmetry and degrees of freedom were adjusted using Kenward-Rogers method.

The purpose of using a positive control (moxifloxacin) is to demonstrate that the study procedures are adequate to detect a placebo subtracted change from baseline (ΔΔQTc) effect of 5 ms. This is substantiated if the lower bound of the two-sided 90% CIs around the mean ΔΔQTcF between moxifloxacin and placebo (ie, the estimates for the differences in the treatment by hour interaction least squares means between moxifloxacin and placebo) excludes 5 ms and fit the usual time course associated with moxifloxacin induced QT prolongation.21,22

Results

Diurnal variation of QTcF measurements at baseline day

The diurnal variation, shown as the mean QTcF during the 24 hours of Day 1 (baseline day) of each period are presented in Figure 2. The mean QTcF at all time points were similar in all five periods, with a maximum noted in the mid-morning (~1000 hours) and a minimum noted during late afternoon (1800 hours). This diurnal change exceeded the threshold for a positive TQTS (5 ms).

QTcF changes induced by moxifloxacin

The estimates of ΔΔQTcF (baseline adjusted change from placebo) and the associated 90% two-sided CIs are presented in Table 1 and Figure 3. The maximum changes in moxifloxacin induced QTcF were identified at 1 hour using any of the four baselines and the estimates of maximum mean change were quite similar (TM\textsubscript{EACH} + 19.9 ms, TM\textsubscript{MEAN} + 20.0 ms, TM\textsubscript{P1} + 20.2 ms, and PD\textsubscript{EACH} + 20.7 ms). Furthermore, the moxifloxacin induced QTcF prolongation was detected from 0.5 to 12 hours postdose using all four baselines: lower confidence limit (LCL) excluded 5 ms.

Variability associated with different baselines

Estimates of variability of each baseline are shown in Table 2 as between and within subject standard deviations (SDs). The within subject SDs were TM\textsubscript{EACH} 5.59 ms, TM\textsubscript{MEAN} 5.90 ms, TM\textsubscript{P1} 6.90 ms, and PD\textsubscript{EACH} 7.41 ms. The between subject variability was largest with the TM\textsubscript{EACH} baseline, slightly smaller with the TM\textsubscript{P1} baseline, and smallest with the TM\textsubscript{MEAN} or PD\textsubscript{EACH} baselines.

Discussion

ICH E14 guidance states that the propensity of any new drug to increase the QT interval needs to be assessed and should be baseline corrected. The primary endpoint of this study is not the maximum QT/QTc change but the limits of the CI associated with this change. Consequently, choice of TQTS design should consider the impact of baseline method on QT interval variability.

![Figure 1 Description of the four baseline methods.](image-url)

Notes: Blue: baseline ECG recording; full rectangle, 24 hours recording; partially empty rectangle, single time-point recording. Yellow: On drug ECG recording.
Figure 2 QTcF (Mean ± SE) recorded during the five baseline days.

Abbreviations: QTcF, QT Fridericia’s correction. SE, standard error.

Table 1 Estimate placebo-corrected change from time-matched baseline QTcF with associated 90% two-sided confidence intervals

<table>
<thead>
<tr>
<th>Time point</th>
<th>24 hour, each period (TM each)</th>
<th>Mean of 24 hour (TM mean)</th>
<th>1st Period (TM P1)</th>
<th>Predose, each period (PD each)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>24 hour</td>
<td>Diff</td>
<td>LCL</td>
<td>UCL</td>
</tr>
<tr>
<td>Day 4</td>
<td>0.0</td>
<td>7.5</td>
<td>4.59</td>
<td>10.41</td>
</tr>
<tr>
<td>Day 4</td>
<td>0.5</td>
<td>15.7</td>
<td>12.83</td>
<td>18.66</td>
</tr>
<tr>
<td>Day 4</td>
<td>1.0</td>
<td>19.9</td>
<td>16.99</td>
<td>22.81</td>
</tr>
<tr>
<td>Day 4</td>
<td>1.5</td>
<td>17.9</td>
<td>14.97</td>
<td>20.79</td>
</tr>
<tr>
<td>Day 4</td>
<td>2.0</td>
<td>17.8</td>
<td>14.88</td>
<td>20.70</td>
</tr>
<tr>
<td>Day 4</td>
<td>3.0</td>
<td>18.9</td>
<td>15.94</td>
<td>21.81</td>
</tr>
<tr>
<td>Day 4</td>
<td>4.0</td>
<td>19.3</td>
<td>16.33</td>
<td>22.26</td>
</tr>
<tr>
<td>Day 4</td>
<td>8.0</td>
<td>14.0</td>
<td>11.14</td>
<td>16.91</td>
</tr>
<tr>
<td>Day 4</td>
<td>10.0</td>
<td>9.3</td>
<td>6.43</td>
<td>12.20</td>
</tr>
<tr>
<td>Day 4</td>
<td>12.0</td>
<td>9.5</td>
<td>6.62</td>
<td>12.39</td>
</tr>
<tr>
<td>Day 4</td>
<td>16.0</td>
<td>7.5</td>
<td>6.61</td>
<td>10.38</td>
</tr>
<tr>
<td>Day 5</td>
<td>24.0</td>
<td>6.9</td>
<td>3.95</td>
<td>9.77</td>
</tr>
<tr>
<td>Day 5</td>
<td>36.0</td>
<td>0.1</td>
<td>–2.82</td>
<td>2.94</td>
</tr>
<tr>
<td>Day 6</td>
<td>48.0</td>
<td>0.4</td>
<td>–2.50</td>
<td>3.32</td>
</tr>
<tr>
<td>Day 7</td>
<td>72.0</td>
<td>–3.2</td>
<td>–6.08</td>
<td>–0.26</td>
</tr>
</tbody>
</table>

Abbreviations: TM, time-matched baseline; PD, predose baseline; QTcF, QT Fridericia’s correction; Diff, difference (ms) between Moxifloxacin and placebo; LCL, lower bound of the confidence interval (ms); UCL, upper bound of the confidence interval (ms).
Because QTcF is affected by the time of day, subject activity, and autonomic tone changes, the collection of multiple ECG recordings prior to dosing is recommended. To analyze the effect of treatment on QTcF prolongation, the baseline has to be defined and the change from baseline (ΔQTcF) for each subject has to be calculated. The ΔQTcF is then subjected to an ANCOVA where the baseline value is included as a covariate in order to improve the precision of the treatment comparisons. The EMEA, CPMP/EWP/2863/99 recommends that whether the actual outcome (QTc) or change from baseline variable (ΔQTc) is used in the analysis, the baseline value should be included as a covariate.

Senn discussed the issue of subtracting the corresponding baseline from the associated outcome value before analysis (ie analyzing ΔQTcF in our study) and stressed that if the baselines were not strongly predictive of the outcome, then the variability of the resulting estimator (ΔQTcF) would be increased. This has implications for the choice of a time-matched or a predose baseline. If there were no evidence of any diurnal pattern in the QTcF changes, then using a predose baseline would result in higher precision of the estimator. In addition, because of day to day QT variability, a predose baseline may reduce the variability in a single dose study, especially if T_max is expected within a few hours postdose.

**Table 2** Within- and between-subject standard deviations (SD)

<table>
<thead>
<tr>
<th>Baseline</th>
<th>QTcF</th>
<th>Within-subject SD (ms)</th>
<th>Between-subject SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>24 hour, each period (TM_{EACH})</td>
<td>5.59</td>
<td>9.61</td>
<td></td>
</tr>
<tr>
<td>24 hour, mean of all periods (TM_{MEAN})</td>
<td>5.90</td>
<td>3.13</td>
<td></td>
</tr>
<tr>
<td>24 hour, 1st period (TM_{P1})</td>
<td>6.90</td>
<td>5.71</td>
<td></td>
</tr>
<tr>
<td>Predose, each period (PDM_{EACH})</td>
<td>7.41</td>
<td>3.50</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** TM, time-matched baseline. PD, predose baseline. SD, standard deviation.
Disclosures

All authors were employees of MDS Pharma services at the time of the study and have no conflict of interest to disclose.

References


